77111-77-4

Basic information

• Product Name: 2-Chloro-9-(tetrahydropyran-2-yl)adenine
• Synonyms: 2-Chloro-9-(tetrahydropyran-2-yl)adenine;2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine(WXC06641);2-CHLORO-9-(TETRAHYDRO-2H-PYRAN-2-YL)-9H-PURIN-6-AMINE
• CAS NO: 77111-77-4
• Molecular Formula: C₁₀H₁₂ClN₅O
• Molecular Weight: 253.69
• Mol File: 77111-77-4.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform, DCM, DMF, Ether
• CAS DataBase Reference: 2-Chloro-9-(tetrahydropyran-2-yl)adenine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-9-(tetrahydropyran-2-yl)adenine(77111-77-4)
• EPA Substance Registry System: 2-Chloro-9-(tetrahydropyran-2-yl)adenine(77111-77-4)

Safety Data

• Hazardous Substances Data: 77111-77-4(Hazardous Substances Data)

Usage

Description

2-Chloro-9-(tetrahydropyran-2-yl)adenine is an organic compound that serves as a key intermediate in the synthesis of various adenine derivatives. It is characterized by the presence of a chloro group at the 2nd position and a tetrahydropyran-2-yl group at the 9th position of the adenine molecule. This unique structure endows it with potential applications in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
2-Chloro-9-(tetrahydropyran-2-yl)adenine is used as an intermediate in the synthesis of 2,8-Dihydroxyadenine (D450105), a derivative of adenine. 2-Chloro-9-(tetrahydropyran-2-yl)adenine is known to accumulate in 2,8-Dihydroxyadenine Urolithiasis, a condition characterized by the formation of kidney stones due to the accumulation of 2,8-dihydroxyadenine. The synthesis of this derivative aids in the development of treatments and diagnostic methods for this condition.
Used in Chemical Research:
2-Chloro-9-(tetrahydropyran-2-yl)adenine can also be utilized in chemical research for the development of new adenine-based compounds with potential applications in various fields. Its unique structure allows for further functionalization and modification, enabling the creation of novel molecules with specific properties and functions.

Upstream product

• 5451-40-1 2,6-dichloropurine 
• 5451-40-1 2,6 dichloropurine 
• 110-87-2 3,4-dihydro-2H-pyran 
• 20419-68-5 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 5451-40-1 2,6-dichloro-7H-purine 

Downstream Products

• 1050495-33-4 2-[(cyclohexylmethyl)oxy]-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 1293916-30-9 C₂₈H₃₄N₆O₂ 
• 1293917-23-3 C₂₇H₃₂N₆O₂ 
• 1293916-29-6 C₁₇H₂₀IN₅O₂ 
• 1208368-10-8 phenylmethyl 2-{3-[6-amino-2-(butyloxy)-8-(methyloxy)-9H-purin-9-yl]propyl}-1-piperidinecarboxylate 
• 1208368-13-1 phenylmethyl 3-{[6-amino-2-(butyloxy)-8-(methyloxy)-9H-purin-9-yl]methyl}-1-piperidinecarboxylate 
• 1050495-36-7 8-bromo-2-[(cyclohexylmethyl)oxy]-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 1050495-39-0 2-[(cyclohexylmethyl)oxy]-8-(methoxy)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 1050495-44-7 2-[(cyclohexylmethyl)oxy]-8-(methoxy)-9-(tetrahydro-2H-pyran-4-ylmethyl)-9H-purin-6-amine 
• 1050491-31-0 6-amino-2-[(cyclohexylmethyl)oxy]-9-(tetrahydro-2H-pyran-4-ylmethyl)-7,9-dihydro-8H-purin-8-one 
• 1050495-42-5 2-[(cyclohexylmethyl)oxy]-8-(methyloxy)-9H-purin-6-amine trifluoroacetate 
• 1061226-09-2 methyl 4-[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](benzyl)amino]-4-oxobutanoate 
• 1061457-47-3 N-[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]-N-benzylacetamide 
• 1061457-46-2 6-amino-9-[3-(benzylamino)propyl]-2-butoxy-7,9-dihydro-8H-purin-8-one 

Relevant articles and documents

COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

The present invention provides compounds of Formula (I) shown above and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.

PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS

There are provided substituted purine and 3-deazapurine analogues, which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune-related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives

We report the synthesis and biological evaluation of a new series of 8-oxoadenines substituted at the 9-position with a 4-piperidinylalkyl moiety. In vitro evaluation of the piperidinyl-substituted oxoadenines 3a-g in human TLR7- or TLR8-transfected HEK293 cells and in human PBMCs indicated that TLR7/8 selectivity/potency and cytokine induction can be modulated by varying the length of the alkyl linker. Oxoadenine 3f containing a 5-carbon linker was found to be the most potent TLR7 agonist and IFNα inducer in the series whereas 3b possessing a 1-carbon linker was the most potent TLR8 agonist.